Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1615 1644 1674 1793
This examiner grants 46% of resolved cases
Julia Anne Lorrain Rossi serves in Tech Center 1700 and Art Unit 1615. She has 35 resolved cases, with an allowance rate of 45.7 percent. This indicates that fewer than half of the cases she resolves result in a patent grant.
The interview lift is 61.3 percent, which is a very high value and suggests that interviews are a critical tool for success. The median days to allowance is 1309, which is a relatively long timeline for the prosecution process. These 35 resolved cases provide a clear picture of the examiner's tendencies in Tech Center 1700.
Practitioners should prioritize interviews given the 61.3 percent lift, which is one of the highest observed. Despite the 45.7 percent allowance rate, the high lift suggests that direct communication is a very effective strategy. The 1309 day median pendency is an important factor for setting client expectations in Art Unit 1615.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18003462 | GROWTH AND SITE-SPECIFIC ORGANIZATION OF MICRO-SCALE BIMOLECULAR DEVICES ON LIVING CELLS | Final Rejection | The Johns Hopkins University |
| 17926748 | INTERFERON- INDUCING OLIGONUCLEOTIDE DUPLEXES AND METHODS OF USE | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18719447 | USE OF ISOXAZOLINECARBOXAMIDE FOR SPROUT INHIBITION | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 17983420 | HUMAN T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA CELL STRAIN AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18722324 | SOLID FRAGRANCING COMPOSITION | Final Rejection | L'OREAL |
| 17160750 | EYELASH COMPOSITIONS CONTAINING SUGAR | Final Rejection | L'OREAL |
| 18100456 | INTRANASAL VACCINES AND THERAPEUTICS FOR RESPIRATORY DISEASES | Final Rejection | UNIVERSITY OF HOUSTON SYSTEM |
| 18713834 | HAIR TREATMENT METHOD | Final Rejection | KAO CORPORATION |
| 18889021 | BIOMIMETIC INTRAOCULAR DRUG DELIVERY SYSTEM FOR TREATMENT OF RETINOBLASTOMA AND METHODS THEREOF | Non-Final OA | THE UNIVERSITY OF HONG KONG |
| 18016165 | THERAPEUTIC USE OF GLUCAGON DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASE | Final Rejection | HANMI PHARM. CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy